摘要
目的观察噻托溴铵(思力华)与布地奈德福莫特罗粉联合吸入对重度、极重度(Ⅲ-Ⅳ级)慢性阻塞性肺疾病(COPD)稳定期患者的疗效。方法选取2011年9月至2012年9月于本院呼吸科门诊就诊的60例稳定期重度、极重度COPD患者,采用完全随机法分成3组(即思力华组、信必可都保组、思力华与信必可都保联合组),共治疗6个月。分别于治疗前和治疗后测定患者肺功能(FEV1,FEV1/FVC%,FEV1占预计值%)、记录圣乔治呼吸问卷评分,统计半年总急性加重次数,采用分组对比治疗方法。结果思力华组、信必可都保组、联合组肺功能、圣乔治呼吸问卷评分均较治疗前改善(P<0.05),联合组各项指标改善更明显(P<0.05)。联合组急性加重次数较其余两组明显减少(P〈0.05)。结论思力华吸入剂联合信必可都保吸入剂治疗稳定期重度、极重度COPD疗效肯定,优于单一种药物治疗,值得临床进一步推广应用。
Objective To evaluate the effects of Spirva Combined Symbicort Turbuhaler for the treatment in patients with severe to profound（Ⅲ-Ⅳ）stable chronic obstructive pulmonary disease（COPD）.Methods Sixty patients with severe to profound stable COPD were recruited from outpatient of the People＇s Hospital of Jieyang between Sep.2011 and Sep.2012.The patients were randomly divided into three groups（Spirva group,Symbicort Turbuhaler group and combination group）.All patients had received treatment for 6 months.Before and after the treatment,lung function（FEV1,FEV1/FVC% ,percentage of FEV-1 and predict value）, the St.George’s respiratory questionnaire（SGRQ）score were assessed.The number of exacerbations were also recorded during 6 months.Results Lung function and the SGRQ score were improved in all groups compared with baseline（P 0.05）,especially in the combination group（P 0.05）.Compared with the Spirva group and the Symbicort Turbuhaler group,the combination therapy significantly decreased the incidence of exacerbations（P 0.05）.Conclusion Spirva Combined Symbicort Turbuhaler is effective for the treatment in patients with severe to profound（Ⅲ-Ⅳ）stable chronic obstructive pulmonary disease（COPD）,which could further advance efficacy than Spirva or Symbicort Turbuhaler.It is worthily recommended in the clinical application.
出处
《中国现代药物应用》
2013年第11期9-11,共3页
Chinese Journal of Modern Drug Application
关键词
思力华
信必可都保
联合用药
慢性阻塞性肺疾病
Spirva
Symbicort Turbuhaler
Combination therapy
Chronic obstructive pulmonary disease
